ROCKVILLE, Md., Sept. 6, 2005 (PRIMEZONE) -- Cytomedix, Inc. (AMEX:GTF) today announced that it has appointed The Wall Street Group, Inc., as its financial public relations advisor.
The Wall Street Group, based in New York City, was founded 46 years ago and is the oldest firm of its kind specializing in developing investment community sponsorship for the shares of growth companies. The firm will concentrate on introducing Cytomedix to brokers, analysts, money managers, institutional investors and investment bankers.
"The Wall Street Group's excellent reputation within the financial community will enable our Company to increase investor awareness and visibility, particularly among institutional investors," stated Cytomedix Chairman and Chief Executive Officer Kshitij Mohan, Ph.D. "The firm's expertise will be invaluable as our Company positions itself for anticipated expansion and future growth."
About the Company
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for uses in the treatment of wounds and other applications. The current offering is the AutoloGel(tm) system, a technology that utilizes an autologous platelet gel composed of multiple growth factors and fibrin matrix. The company is conducting a controlled, blinded, prospective, multi-center clinical trial on the use of its technology in healing diabetic foot ulcers. Cytomedix is working with healthcare providers to offer this advanced therapy at the point-of-care in multiple settings. Additional information is available at: http://www.cytomedix.com.
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, the success of new sales initiatives, governmental regulation, acceptance by the medical community and competition. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc.